[30 August 2012]
Products Affected - Description
All presentations are available.
Reason for the Shortage
- Apotex relaunched leflunomide tablets in August 2011.
- Teva has had leflunomide tablets on shortage due to unavailability of raw material.
- Sandoz has had leflunomide tablets on shortage due to increased demand and delay of raw material.
Available Products
Leflunomide tablets, Apotex
10 mg, 30 count (NDC 60505-2502-01)
10 mg, 1000 count (NDC 60505-2502-03)
20 mg, 30 count (NDC 60505-2503-01)
20 mg, 1000 count (NDC 60505-2503-03)
Leflunomide tablets, Sandoz
10 mg, 30 count (NDC 00781-5056-31)
20 mg, 30 count (NDC 00781-5056-31)
Arava, Sanofi-Aventis
10 mg, 30 count (NDC 00088-2160-30)
20 mg, 30 count (NDC 00088-2161-30)
Leflunomide tablets, Teva
10 mg, 30 count (NDC 00093-0173-56)
20 mg, 30 count (NDC 00093-0174-56)
Estimated Resupply Dates
All presentations are available.
Updated
August 30, 2012; June 20, 2012; May 9, 2012; March 9, 2012; February 1, 2012; December 6, 2011; November 21, 2011; October 21 and 19, 2011; September 7, 2011; August 1, 2011; June 24, 2011; May 3, 2011; April 22, 2011; April 6, 2011; March 11, 2011; February 9, 2011; January 21, 2011; January 13, 2011; January 12, 2011; December 22, 2010, December 21, 2010, University of Utah, Drug Information Service. Copyright 2012, Drug Information Service, University of Utah, Salt Lake City, UT.
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins